Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. MSB
MSB logo

MSB News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

MSB News

MESOBLAST GETS FDA IND APPROVAL TO INITIATE REGISTRATIONAL TRIAL FOR RYONCIL

Apr 08 2026moomoo

MESOBLAST LTD - FDA Approves RYONCIL IND for DMD Registration Trial

Apr 08 2026moomoo

MESOBLAST LTD - RYONCIL QUARTERLY NET REVENUE RISES TO US$30.3M

Apr 07 2026moomoo

Market Dynamics and Corporate Changes

Mar 13 2026CNBC

Mesabi Trust (MSB) Declares $0.26 Quarterly Dividend Payable February 20

Jan 19 2026seekingalpha

Mesoblast Receives FDA Feedback for BLA Filing of rexlemestrocel-L

Jan 19 2026NASDAQ.COM

Mesoblast Reports 60% Revenue Growth to $35.1 Million in Q4

Jan 09 2026Globenewswire

Mesoblast Appoints New Chair to Drive Commercialization Efforts

Jan 01 2026Globenewswire

MSB Events

01/02 05:10
Mesoblast Appoints Philip Facchina as New Non-Executive Chair
Mesoblast announced that Jane Bell will retire from her role as chair and will remain on the board as a non-executive director. The board has unanimously appointed Philip Facchina to the role of non-executive chair. Facchina joined the Mesoblast board in March 2021.
10/17 16:06
Mesabi Trust raises quarterly distribution to 39c per share from 35c
The Trustees of Mesabi Trust declared a distribution of 39c per Unit of Beneficial Interest payable on November 20, 2024 to Mesabi Trust Unitholders of record at the close of business on October 30, 2024. This compares to a 35c per Unit distribution declared for the same period last year.
09/11 12:00
Mesabi Trust rises 27.8%
Mesabi Trust is up 27.8%, or $4.66 to $21.42.

MSB Monitor News

No data

No data

MSB Earnings Analysis

No Data

No Data

People Also Watch